The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU)

Clinical and Experimental Immunology

Volumn 118, Issue 3, 1999, Pages 364-370

  Wallace, Graham R ^b   Whiston, R A ^c   Stanford, M R ^c   Wells, G M A ^a   Gearing, A J H ^a   Clements, J M ^a  

^a British Biotechnology   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

Experimental autoimmune uveoretinitis; Metalloproteinase inhibitor

Indexed keywords

BB 1101; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAT; RETINA; SUBCUTANEOUS DRUG ADMINISTRATION; UVEORETINITIS;

ANIMALS; ARRESTIN; AUTOIMMUNE DISEASES; DEXAMETHASONE; DRUG COMBINATIONS; MALE; MATRIX METALLOPROTEINASES; PENTOXIFYLLINE; PROTEASE INHIBITORS; RATS; RATS, INBRED LEW; RETINA; RETINITIS; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 0032747030     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01066.x     Document Type: Article

References (35)

1. 1 Forrester JV. New concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye 1992; 6:433-46.
2. 2 Lightman S, Greenwood J. Effect of lymphocyte infiltration on the blood retinal barrier in experimental autoimmune uveoretinitis. Clin Exp Immunol 1992; 89:165-9.
3. 3 Whitcup SM. Involvement of cell adhesion molecules in the pathogenesis of experimental autoimmune uveitis. Ocular Immunol Inflam 1995; 3:53-6.
4. 4 Zaman AG, Edelsten CE, Stanford MR et al. Soluble intercellular adhesion molecule-1 (ICAM-1) as a marker of disease relapse in idiopathic uveoretinitis. Clin Exp Immunol 1994; 95:60-65.
5. 5 Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Pathol 1993; 67:143-50.
6. 6 Uchio E, Kijima M, Tanaka S, Ohno S. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci 1994; 35:2626-31.
7. 7 Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1985; 26:1-9.
8. 8 Woessner JF Jr. The family of matrix metalloproteinases. Ann NY Acad Sci 1994; 156:1-4.
9. 9 Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, TIMP, and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36:372-80.
10. 10 Macda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropath Exp Neurol 1996; 55:300-9.
11. 11 Hamdy FC, Fadlon EJ, Cottam D et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994; 69:177-82.
12. 12 Platner JJ, Smine A, Quinn TA. Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. Curr Eye Res 1998; 17:132-40.
13. 13 Di Girolamo N, Verma MJ, McClusky P, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and animals with uveitis. Curr Eye Res 1996; 15:1060-8.
14. 14 Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1998; 39: 1524-9.
15. 15 Watson SA, Tierney G. Matrix metalloproteinase inhibitors - a review. Biodrugs 1998; 9:325-35.
16. 16 Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994; 94:2177-82.
17. 17 Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Clark RL, McGeechan GM, Connolly KM. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995; 182:449-57.
18. 18 Dick AD, Cheng YF, McKinnon A, Liversidge J, Forrester JV. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. Brit J Ophthalmol 1993; 77:171-5.
19. 19 Wells GMA, Catlin G, Cossins JA, Mangan M, Ward GA, Miller KM, Clements JM. Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with multi-competitor cDNA standard. Glia 1996; 18:332-40.
20. 20 Anthony DC, Miller KM, Fearn S et al. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998; 87:62-72.
21. 21 Clements JM, Cossins JA, Wells GMA et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J Neuroimmunol 1997; 74:85-94.
22. 22 Hughes PM, Wells GMA, Clements JM et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998; 121:481-94.
23. 23 Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995, 44:345-9.
24. 24 Leidtke W, Canella B, Mazzaccaro RJ, Clements JM, Miller KM, Wucherpfennig KW, Gearing AJH, Raine CS. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 1998; 44:35-46.
25. 25 Busiek DF, Baragi V, Nehring LC, Parks WC, Welgus HG. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J Immunol 1995; 154:684-491.
26. 26 Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, Sedgwick J. Inhibition of tumour necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996; 26:1018-25.
27. 27 Forrester JV, Huitinga I, Lumsden L, Dijkstra CD. Marrow derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res 1998; 17:426-37.
28. 28 Gearing AJH, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555-7.
29. 29 Black RA, Rauch CT, Kovlovsky CT et al. A metalloproteinase disintegrin that releases tumour necrosis factor α from cells. Nature 1997; 385:729-33.
30. 30 Sartini G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, Caspi RR. Anti-tumour necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 1996; 37:2211-8.
31. 31 De Vos AF, van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A. Systemic anti-tumour necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995; 61:667-75.
32. 32 Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996; 20: 11634-40.
33. 33 Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro ST. Metalloproteinase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996; 93:3942-6.
34. 34 Gery I, Wiggert B, Redmond TM, Kuwubara T, Crawford MA, Vistica BP, Chader GJ. Uveoectinitis and pincalitis induced by immunisation with interphotoreceptor binding protein. Invest Ophthalmol Vis Sci 1986; 27:1296-300.
35. 35 Ferrick MR, Thurau SR, Oppenheim MH, Herbort CP, Ni M, Zacheriaz CO, Matsushima K, Chan CC. Ocular inflammation stimulated by intravitreal interleukin-8 and interleukin-1. Invest Ophthalmol Vis Sci 1991; 32:15.14-9.